BACKGROUND:Available data suggest that pregnancy exposure to interferon-beta might result in lower mean birth weight and preterm birth.
OBJECTIVE:To determine the effect of interferon-beta exposure during pregnancy on pregnancy outcomes in multiple sclerosis patients.
METHODS:We compared the pregnancy outcomes of women exposed to interferon-beta with pregnancies unexposed to disease-modifying therapies. Women were enrolled into the German Multiple Sclerosis and Pregnancy Registry. A standardized questionnaire was administered during pregnancy and postpartum. Detailed information on course of multiple sclerosis and pregnancy, concomitant medications, delivery, and outcome of pregnancy was obtained.
CONCLUSIONS:Interferon-beta exposure during early pregnancy does not influence the mean birth weight, risk of preterm birth, or other adverse pregnancy outcomes. Our study provides further reassurance that interferon-beta treatment can be safely continued up until women become pregnant.